fashion -WSS

fashion

author：hotspot 2025-08-12 06:42:51 - browse：396

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： RSV vaccines may be linked to small increased risk of developing GBS

hotspot

focus

WSS

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

AstraZeneca loses challenge to Medicare drug price negotiation

RSV vaccines may be linked to small increased risk of developing GBS

AstraZeneca loses challenge to Medicare drug price negotiation

Medical device lobby: We're tired of waiting on Medicare coverage

AstraZeneca loses challenge to Medicare drug price negotiation

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Sports medicine is finally prioritizing gender equality

FogPharma raises $145 million in rare Series E round

How one medical school became remarkably diverse

Biotech companies concerned about China biosecurity crackdown

Jerome Adams on the need for new antivirals for Covid

Obesity now affects over 1 billion people worldwide, study finds

At least 13 dead in Texas as scorching temps continue

ALS groups 'won't be played again' by the FDA, drug sponsors

23andMe had bad news about my health. I wish a person had delivered it

House looks to weaken Medicare negotiation

focus

International team creates first chimeric human

FogPharma raises $145 million in rare Series E round

Flu vaccine offering decent levels of protection this winter, new data show

Medical device lobby: We're tired of waiting on Medicare coverage

Pfizer highlights cancer drugs it thinks could reignite investor interest

International team creates first chimeric human

hotspot

Wikipedia

focus

Wikipedia